Diagnosis and treatment of myelofibrosis: a personal perspective
نویسندگان
چکیده
منابع مشابه
Bicytopenia Secondary to Autoimmune Myelofibrosis as the First Presentation of an Undiagnosed Systemic Lupus Erythematosus: A Rare Case Report
Autoimmune myelofibrosis (AIMF) is considered as an infrequent cause of bone marrow fibrosis (BMF) and a rare complication of systemic lupus erythematosus (SLE). Due to its rarity, it is mistakenly diagnosed as primary myelofibrosis (MF). We describe the clinicopathologic features of a secondary form of AIMF in a 33- year- old female patient with an undiagnosed SLE which presented with acute b...
متن کاملPSYCHOSOCIAL CHALLENGES OF INFERTILITY FROM THE PERSPECTIVE OF IRANIAN WOMEN: A QUALITATIVE STUDY
Background & Aims: Although infertility is a medical condition, its dimensions and consequences go beyond the biological and physical realms and have psychosocial dimensions and consequences. This is especially important for women, given the socio-cultural requirements of Iranian society. The aim of the present study is to explore the psychosocial challenges of infertility from the perspective ...
متن کاملEvaluation the efficiency of health watch checkup in the diagnosis and treatment of diseases from the perspective of Hamedan police force
Introduction: The health watch checkup project (HWCP) has been conducted in the armed forces since many years ago in order to increase and improve the health condition between the employees. It may be of great importance because of assessing the mental and physical health of armed forces employees; however, conducting the said checkup requires considerable money and time. To analyze the efficie...
متن کاملMyelofibrosis due to Secondary Hyperparathyroidism in a Case of Celiac Disease
Myelofibrosis is reported in patents with primary hyperparathyroidism. It is also was reported in patents with sec- ondary hyperparathyroidism due to end-stage renal disease or Vitamin D dependent rickets .We present a case of celiac disease and osteomalacia which leads to secondary hyperparathyroidism and myelofibrosis.
متن کاملDefinition and management of ruxolitinib treatment failure in myelofibrosis
Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF). Several other JAK inhibitors are in development with some currently undergoing phase-3 clinical trial testing. None of the currently available JAK inhibitors are specific to mutant JAK2; their mechanism of ac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013